Abstract
This study was designed to evaluate insulin resistance and plasma levels of visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome (PCOS).A total of 37 premenopausal PCOS patients with (n = 18, mean (SD) age: 27.5 (5.7 years) or without obesity (n = 19, mean (SD) age: 23.7 (3.1) years) and healthy volunteers (n = 18, mean (SD) age:29.8 (4.1) years) were included in this study. Data on clinical characteristics, glycemic parameters and lipid parameters were recorded for each subject as were plasma visfatin and resistin levels. Mean (SD) HOMA-IR values were significantly higher in obese PCOS patients (3.4 (1.7)) compared with non-obese PCOS patients (2.0 (1.2), p<0.01) and controls (1.6 (0.8), p<0.01). No significant difference was noted between study groups in terms of plasma resistin (ng/mL) or visfatin (ng/mL) levels. There was no correlation between serum plasma visfatin (r = 0.127, p = 0.407) and resistin (r = -0.096, p = 0.544) levels and HOMA-IR. In conclusion, our findings revealed increased likelihood of metabolic and dyslipidemic manifestations in obese compared to non-obese PCOS patients, while no significant difference was noted in visfatin and resistin levels among PCOS patients in terms of co-morbid obesity and in comparison to controls.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19–25.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanisms and implications for pathogenesis. Endocr Rev 1997; 18: 774–800.
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Rev 2012; 33: 981–1030.
Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897–9.
Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–74.
Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28: 341–59.
Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med 2008; 26: 39–44.
Seow KM, Hwang JL, Wang PH, Ho LT, Juan CC. Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome. Hum Reprod 2011; 26: 2869–73.
Chen X, Jia X, Qiao J, Guan Y, Kang J. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol 2013; 50: R21–37.
Carmina E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front Horm Res 2013; 40: 40–50.
Goodman N, Bledsoe M, Cobin R, et al. American Association of Clinical Endocrinologists Hyperandrogenism Guidelines. Endocrine Practice 2001; 7: 120–34.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80: 2586–93.
Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000; 15: 1266–74.
Vrbikova J, Grimmichova T, Dvorakova K, Hill M, Stanická S, Vondra K. Family history of diabetes mellitus determines insulin sensitivity and beta cell function in polycystic ovary syndrome. Physiol Res 2008; 57: 547–53.
Mahmoud MI, Habbeb F, Kasim K. Reproductive and biochemical changes in obese and non obese polycystic ovary syndrome women, Alex J Med (2014), http://dx.doi.org/10.1016/j.ajme.2014.03.002.
Manco M, Castagneto-Gissey L, Arrighi E, et al. Insulin dynamics in young women with polycystic ovary syndrome and normal glucose tolerance across categories of body mass index. PLoS One 2014; 9: e92995.
Guzick DS. Cardiovascular risk in women with polycystic ovarian syndrome. Semin Reprod Endocrinol 1996; 14: 45–9.
Conway GS, Agrawall R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 37: 119–26.
Rajkhowa M, Bichnell J, Jones M, Clayton RN. Insulin sensitivity in women with polycystic ovary syndrome: Relationship to hyperandrogenemia. Fertil Steril 1994; 61: 605–12.
Barber TM, Franks S. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol 2013; 373: 68–76.
Wojciechowski P, Lipowska A, Rys P, et al. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia 2012; 55: 2636–45.
Guducu N, Isci H, Gormus U, Yigiter AB, Dunder I. 2012 Serum visfatin levels in women with polycystic ovary syndrome. Gynecol Endocrinol 2012; 28: 619–23.
Lajunen TK, Purhonen AK, Haapea M, et al. Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. Eur J Clin Invest 2012; 42: 321–8.
Olszanecka-Glinianowicz M, Madej P, Zdun D, et al. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2012; 162: 55–61.
Ingelsson E, Larson MG, Fox CS, et al. Clinical correlates of circulating Visfatin levels in a community based sample. Diabetes Care 2007; 30: 1278–80.
Yildiz BO, Bozdag G, Otegen U, et al. Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerantwomen with PCOS. Reprod Biomed Online 2010; 20: 150–5.
Kowalska I, Straczkowski M, Nikolajuk A, et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obesewomen with polycystic ovary syndrome. Hum Reprod 2007; 22: 1824–9.
Panidis D, Farmakiotis D, Rousso D, et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med 2008; 19: 406–12.
Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 2006; 91: 5022–8.
Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 2007; 88: 401–5.
Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156: 279–84.
Wang Y, Zhu W. Evaluation of adiponectin, resistin, IL-6, TNF-γ in obese and non-obese women with polycystic ovary syndrome. J Reprod Contracept 2012; 23: 237–44.
Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 361–6.
Lewandowski KC, Szosland K, O’Callaghan C, Tan BK, Randeva HS, Lewinski A. Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices. Mol Genet Metab 2005; 85: 61–9.
Seow KM, Juan CC, Wu LY, et al. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod 2004; 19: 48–53.
Zhang J, Zhou L, Tang L, Xu L. The plasma level and gene expression of resistin in polycystic ovary syndrome. Gynecol Endocrinol 2011; 27: 982–7.
Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003; 149: 331–5.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Gul, O.O., Cander, S., Gul, B. et al. Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome. Eur Cytokine Netw 26, 73–78 (2015). https://doi.org/10.1684/ecn.2015.0370
Published:
Issue Date:
DOI: https://doi.org/10.1684/ecn.2015.0370